Endonovo Therapeutics, Inc.
ENDV · OTC
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $133 | $162 |
| Gross Profit | $0 | $0 | -$133 | -$162 |
| % Margin | – | – | – | – |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | $231 | $65 | $226 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $249 | $0 | $162 | $162 |
| Operating Expenses | $249 | $231 | $227 | $388 |
| Operating Income | -$249 | -$231 | -$360 | -$388 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | -$309 | -$302 | -$309 | -$309 |
| Pre-Tax Income | -$558 | -$533 | -$669 | -$697 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$558 | -$533 | -$669 | -$697 |
| % Margin | – | – | – | – |
| EPS | 0 | -0.001 | -0.001 | -0.001 |
| % Growth | 100% | 58.3% | -20% | – |
| EPS Diluted | 0 | -0.001 | -0.001 | -0.001 |
| Weighted Avg Shares Out | 0 | 1,097,921 | 543,871 | -1,022,166 |
| Weighted Avg Shares Out Dil | 0 | 1,097,921 | 543,871 | -1,022,166 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $309 | $309 | $309 | $309 |
| Depreciation & Amortization | $0 | $0 | $133 | $162 |
| EBITDA | -$249 | -$224 | -$227 | -$226 |
| % Margin | – | – | – | – |